Pharma News, Research & Solutions CSR News

Chairman and CEO Alex Gorsky Profiled by the Financial Times About Johnson & Johnson's Work on a Potential Covid-19 Vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO's people-first approach to leadership at our healthcare company.

Johnson & Johnson scientists are fast at work on a potential vaccine for Covid-19 that our company plans to provide on a not-for-profit basis.

“I’m a Scientist Working on a Potential Covid-19 Vaccine”: Meet a Researcher Who's Studying a Promising Candidate

Roland Zahn, Ph.D., a Janssen scientist and expert in viral vaccines, was at the front lines of research during the Ebola outbreak. Today he and his team are working at record speed to help deliver a potential vaccine for the novel coronavirus.

Weeks before many people had even heard of the novel coronavirus, Roland Zahn, Ph.D., was already studying the disease—specifically, how it could be stopped.​

The Road to a Vaccine, Ep. 1: How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There

Multimedia with summary

This new eight-episode educational video series will examine the latest efforts to respond to the COVID-19 pandemic and break down the complex process of developing a vaccine.

Accelerating Results for Patients through STAR

Multimedia with summary

Alexion’s vision is to continuously raise the bar to deliver on patient expectations with solutions designed for them as people – meaning we want to take the time to understand their social and emotional lives, as well as their medical condition.

Ramping Up Manufacturing to Help Address COVID-19


As the number of confirmed COVID-19 cases increased in Asia and began to spread to other regions around the world, a team of employees at Gilead’s manufacturing site in La Verne, California met in the early morning of Monday, Feb. 3.

The topic of the meeting: How quickly could the site begin to formulate, fill, package and ship Gilead’s investigational COVID-19 treatment, remdesivir?

Statement from Alkermes on Response to COVID-19


At Alkermes, we are closely monitoring and rapidly responding to the impact of COVID-19 on our employees and our communities, and we will continue to update this page periodically. As always, if you have questions for us, please refer to our contact page for information.

Updated: April 3, 2020

American Express’ Commitment to Backing Colleagues, Customers and Communities Affected by COVID-19

Press Release

April 10, 2020 /3BL Media/ - For more than 170 years, American Express has been committed to backing our colleagues, our customers, our partners and the communities we serve around the world. As we navigate the COVID-19 pandemic, this commitment is more important than ever, and we wanted to share an update on some of the actions we’ve taken during this unprecedented time. 

Providing Critical Resources to HCPs in Time of Crisis


Published on March 27, 2020
by Sandra Humbles, Vice President, Global Education Solutions, Johnson & Johnson Medical Devices

Today, the heroic healthcare professionals (HCPs) on the front lines of care in communities around the world need our support more than ever before.

"I Have Never Seen a Moment So Rich in Collaboration, Ingenuity and Acts of Bravery": Johnson & Johnson Announces It Has Identified a Lead Covid-19 Vaccine Candidate

Chairman & CEO Alex Gorsky shares that the company could have the first batches of a Covid-19 vaccine available for emergency-use authorization in early 2021—a substantially accelerated time frame in comparison to the typical vaccine development process.

By Alex Gorsky, Chairman & CEO, 

The Covid-19 pandemic is one of the greatest challenges to our society in living memory.

Yet even as we are heartbroken by the lives lost and the strain on our institutions and communities, countless people have been working tirelessly to offer the world a reason to feel pride, inspiration and hope.

Bayer Employees Volunteer to Conduct SARS-CoV-2 Tests in Newly Established Berlin Laboratory

Multimedia with summary

Our newly established testing laboratory in Berlin which supports the fight against the Corona virus is already running: In the lab, our employees – more than 140 have volunteered – are able to conduct up to 1,000 additional SARS-CoV-2 tests per day. This helps to slow down the spread of the virus as fewer infections remain undetected and infection chains can be better reconstructed.

Follow more Corona virus stories here.


Subscribe to Pharma News, Research & Solutions